Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Wellington Partners is a prominent venture capital firm founded in 1998, headquartered in Munich, Germany, with an additional office in Zurich, Switzerland. With over two decades of experience, the firm has established itself as a key player in the European venture capital landscape, particularly in the life sciences sector. Wellington Partners specializes in investing in early- and growth-stage companies, focusing on therapeutics, medical devices, diagnostics, digital health, and industrial biotechnology. The firm manages assets under management (AUM) totaling approximately €800 million, allowing it to make significant investments in promising startups.
The leadership team at Wellington Partners comprises seasoned professionals with extensive backgrounds in venture capital, entrepreneurship, and the life sciences industry. Their collective expertise enables the firm to provide not only financial resources but also strategic support to portfolio companies. This dual approach enhances the likelihood of success for the startups they back, as they navigate the complex landscape of product development, regulatory approvals, and market entry.
Wellington Partners is recognized for its commitment to fostering innovation in critical healthcare sectors, particularly those addressing urgent medical needs. The firm’s reputation is built on its ability to identify and support groundbreaking technologies that have the potential to transform patient care and improve health outcomes across Europe and beyond.
Wellington Partners focuses on investing in early- and growth-stage life science companies, primarily within Germany and Europe. The firm’s investment strategy is characterized by a commitment to providing substantial financial resources, with typical check sizes ranging from €2 million to €20 million. This financial backing is complemented by strategic support aimed at helping entrepreneurs navigate the challenges of bringing innovative healthcare solutions to market.
The sectors of interest for Wellington Partners include therapeutics, medical devices, diagnostics, digital health, and industrial biotechnology. The firm actively engages in financing rounds, ensuring that its portfolio companies receive the necessary capital to advance through critical stages of development, including preclinical and clinical trials. Additionally, Wellington Partners offers guidance through the regulatory approval processes, which are essential for bringing new medical products to market.
Wellington Partners seeks to partner with visionary founders who are dedicated to making a significant impact in the healthcare sector. The firm values innovation and is particularly interested in companies that address pressing medical challenges. By aligning with entrepreneurs who share this vision, Wellington Partners aims to foster the growth of transformative healthcare solutions that can improve patient outcomes and enhance the quality of care.
Wellington Partners boasts a diverse portfolio of notable investments in the life sciences sector. Among its prominent portfolio companies is **Actelion**, which focuses on developing innovative products for pulmonary arterial hypertension. Another key investment is **Adrenomed**, a company dedicated to rescuing vascular integrity in critically ill patients. **Advanced Medical Balloons (AMB)** specializes in bowel management solutions for critically ill patients, while **Confo Therapeutics** operates a drug discovery platform targeting G protein-coupled receptors (GPCRs).
Additionally, Wellington Partners has invested in **UroMems**, which is developing a smart implant designed to treat male stress urinary incontinence, and **Sidekick Health**, a company that provides digital care solutions for patients with chronic illnesses. These investments reflect Wellington Partners' commitment to supporting innovative companies that are poised to make a significant impact in the healthcare landscape.
The firm’s portfolio not only highlights its focus on life sciences but also demonstrates its strategic approach to investing in companies that address urgent medical needs. By backing these innovative startups, Wellington Partners plays a crucial role in advancing healthcare technologies that can improve patient outcomes and drive industry progress.
Dr. Michael Kauffmann - Managing Partner with extensive experience in venture capital and a focus on life sciences investments.
Dr. Thomas Huber - Partner specializing in healthcare and biotech sectors, known for his strategic insights and support for portfolio companies.
To approach Wellington Partners with a pitch, entrepreneurs should prepare a detailed business plan that outlines their innovative solutions and market potential. While specific submission guidelines are not provided, a well-structured pitch is essential for capturing the firm’s interest. Engaging through warm introductions may also enhance the chances of a successful pitch.
Wellington Partners invests in early- and growth-stage companies, primarily focusing on the life sciences sector. Their investment strategy encompasses both pre-seed and seed stages, as well as growth equity opportunities.
To pitch Wellington Partners, entrepreneurs should prepare a comprehensive business plan that outlines their innovative solutions, market potential, and financial projections. While specific submission guidelines are not provided, a well-structured pitch is essential for capturing the firm’s interest.
Wellington Partners primarily focuses on the life sciences sector, with particular emphasis on therapeutics, medical devices, diagnostics, digital health, and industrial biotechnology. The firm seeks to invest in companies that are addressing critical healthcare challenges.
The typical check size for Wellington Partners ranges from €2 million to €20 million. This range allows the firm to provide substantial financial support to its portfolio companies as they navigate various stages of development.
Wellington Partners primarily invests in Germany and Europe, leveraging its strong presence in these regions to identify and support promising life science companies.
While specific details about the application process are not provided, entrepreneurs are encouraged to present a well-prepared pitch that highlights their innovative solutions and market potential. Engaging with the firm through networking or introductions may also be beneficial.
Wellington Partners offers strategic support to its portfolio companies, assisting them through critical development phases, including preclinical and clinical trials, regulatory approvals, and market entry. This support is designed to enhance the likelihood of success for the startups they back.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.